T1	Claim 1595 1661	Intraperitoneal administration limits cardiotoxicity of verapamil.
T2	Claim 1458 1594	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
T3	Premise 762 869	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
T4	Premise 592 761	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
T5	Premise 876 992	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
T6	Premise 1084 1230	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
T7	Premise 1240 1327	cumulative survival rate was also significantly higher in the combined treatment group.
T8	Premise 1328 1457	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
R1	Support Arg1:T8 Arg2:T1	
R2	Support Arg1:T7 Arg2:T2	
R3	Support Arg1:T6 Arg2:T2	
R4	Support Arg1:T5 Arg2:T2	
